Preliminary clinical assessment of dynamic 18F-fluorodeoxyglucose positron emission tomography/computed tomography for evaluating lymph node metastasis in patients with lung cancer: a prospective study

Takayoshi Shinya, Yoichi Otomi, Michiko Kubo, Mitsuhiro Kinoshita, Katsuya Takechi, Naoto Uyama, Moriaki Yamanaka, Kaori Terazawa, Hiroaki Toba, Yoshimi Bando, Hideki Otsuka, Masafumi Harada

Research output: Contribution to journalArticle

Abstract

OBJECTIVE: We assessed the diagnostic capacity of dynamic fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) and dual-time-point (DTP) PET/CT to explore the optimal scan timing for nodal staging in lung cancer. METHODS: Thirty-four patients with lung cancer underwent dynamic and consecutive DTP PET/CT scans. Two readers visually evaluated FDG uptake within each lymph node (LN) and pulmonary artery (metastatic LN: n = 10; nonmetastatic LN: n = 121). For each dynamic and DTP scan, we compared the maximum standardized uptake value (SUVmax) and the retention index of the SUVmax (RI-SUVmax) between metastatic and nonmetastatic LNs. We compared the diagnostic capacity of the dynamic and DTP scans using receiver operating characteristic (ROC) analyses. RESULTS: In the visual analyses of LN metastases, a sensitivity of 20.0-60.0% and specificity of 97.5-100.0% were identified for the first to third dynamic scans. The sensitivity of the 1-h early and 2-h delayed scans was 80.0% and 90.0%, respectively, whereas the specificity was 66.9% and 47.9%, respectively. The visual analysis of the dynamic second phase had the highest accuracy. Semiquantitative analyses revealed that the SUVmax was significantly higher for metastatic LNs than for nonmetastatic LNs in the dynamic second and third phases and the 1-h early and 2-h delayed phases (p < 0.05 for all). The RI-SUVmax was higher in metastatic LNs than in nonmetastatic LNs for the dynamic scan (p = 0.004) and the DTP scan (p = 0.002). The ROC analyses showed that SUV2 and SUV3 had higher performances with high specificity, high negative predictive value, and high accuracy than the other parameters. The area under the ROC curve of the RI-SUV-dual-time-point had the highest value (0.794) without any significant differences between the area under the ROC curves for all parameters (p > 0.05 for all). CONCLUSIONS: Based on the visual and semiquantitative analyses, 18F-FDG dynamic PET/CT exhibited excellent performance with extremely high specificity in the dynamic second phase.

Original languageEnglish
Pages (from-to)414-423
Number of pages10
JournalAnnals of nuclear medicine
Volume33
Issue number6
DOIs
Publication statusPublished - Jun 1 2019
Externally publishedYes

Fingerprint

Fluorodeoxyglucose F18
Lung Neoplasms
Lymph Nodes
Prospective Studies
Neoplasm Metastasis
ROC Curve
Pulmonary Artery
Positron Emission Tomography Computed Tomography

Keywords

  • Dynamic positron emission tomography (PET)
  • F-18 fluorodeoxyglucose (FDG)
  • Lung cancer
  • Lymph node
  • Lymphatic metastasis

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Preliminary clinical assessment of dynamic 18F-fluorodeoxyglucose positron emission tomography/computed tomography for evaluating lymph node metastasis in patients with lung cancer : a prospective study. / Shinya, Takayoshi; Otomi, Yoichi; Kubo, Michiko; Kinoshita, Mitsuhiro; Takechi, Katsuya; Uyama, Naoto; Yamanaka, Moriaki; Terazawa, Kaori; Toba, Hiroaki; Bando, Yoshimi; Otsuka, Hideki; Harada, Masafumi.

In: Annals of nuclear medicine, Vol. 33, No. 6, 01.06.2019, p. 414-423.

Research output: Contribution to journalArticle

Shinya, Takayoshi ; Otomi, Yoichi ; Kubo, Michiko ; Kinoshita, Mitsuhiro ; Takechi, Katsuya ; Uyama, Naoto ; Yamanaka, Moriaki ; Terazawa, Kaori ; Toba, Hiroaki ; Bando, Yoshimi ; Otsuka, Hideki ; Harada, Masafumi. / Preliminary clinical assessment of dynamic 18F-fluorodeoxyglucose positron emission tomography/computed tomography for evaluating lymph node metastasis in patients with lung cancer : a prospective study. In: Annals of nuclear medicine. 2019 ; Vol. 33, No. 6. pp. 414-423.
@article{f8ab32b8e66049fb9a817fd789c627f0,
title = "Preliminary clinical assessment of dynamic 18F-fluorodeoxyglucose positron emission tomography/computed tomography for evaluating lymph node metastasis in patients with lung cancer: a prospective study",
abstract = "OBJECTIVE: We assessed the diagnostic capacity of dynamic fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) and dual-time-point (DTP) PET/CT to explore the optimal scan timing for nodal staging in lung cancer. METHODS: Thirty-four patients with lung cancer underwent dynamic and consecutive DTP PET/CT scans. Two readers visually evaluated FDG uptake within each lymph node (LN) and pulmonary artery (metastatic LN: n = 10; nonmetastatic LN: n = 121). For each dynamic and DTP scan, we compared the maximum standardized uptake value (SUVmax) and the retention index of the SUVmax (RI-SUVmax) between metastatic and nonmetastatic LNs. We compared the diagnostic capacity of the dynamic and DTP scans using receiver operating characteristic (ROC) analyses. RESULTS: In the visual analyses of LN metastases, a sensitivity of 20.0-60.0{\%} and specificity of 97.5-100.0{\%} were identified for the first to third dynamic scans. The sensitivity of the 1-h early and 2-h delayed scans was 80.0{\%} and 90.0{\%}, respectively, whereas the specificity was 66.9{\%} and 47.9{\%}, respectively. The visual analysis of the dynamic second phase had the highest accuracy. Semiquantitative analyses revealed that the SUVmax was significantly higher for metastatic LNs than for nonmetastatic LNs in the dynamic second and third phases and the 1-h early and 2-h delayed phases (p < 0.05 for all). The RI-SUVmax was higher in metastatic LNs than in nonmetastatic LNs for the dynamic scan (p = 0.004) and the DTP scan (p = 0.002). The ROC analyses showed that SUV2 and SUV3 had higher performances with high specificity, high negative predictive value, and high accuracy than the other parameters. The area under the ROC curve of the RI-SUV-dual-time-point had the highest value (0.794) without any significant differences between the area under the ROC curves for all parameters (p > 0.05 for all). CONCLUSIONS: Based on the visual and semiquantitative analyses, 18F-FDG dynamic PET/CT exhibited excellent performance with extremely high specificity in the dynamic second phase.",
keywords = "Dynamic positron emission tomography (PET), F-18 fluorodeoxyglucose (FDG), Lung cancer, Lymph node, Lymphatic metastasis",
author = "Takayoshi Shinya and Yoichi Otomi and Michiko Kubo and Mitsuhiro Kinoshita and Katsuya Takechi and Naoto Uyama and Moriaki Yamanaka and Kaori Terazawa and Hiroaki Toba and Yoshimi Bando and Hideki Otsuka and Masafumi Harada",
year = "2019",
month = "6",
day = "1",
doi = "10.1007/s12149-019-01350-z",
language = "English",
volume = "33",
pages = "414--423",
journal = "Annals of Nuclear Medicine",
issn = "0914-7187",
publisher = "Springer Japan",
number = "6",

}

TY - JOUR

T1 - Preliminary clinical assessment of dynamic 18F-fluorodeoxyglucose positron emission tomography/computed tomography for evaluating lymph node metastasis in patients with lung cancer

T2 - a prospective study

AU - Shinya, Takayoshi

AU - Otomi, Yoichi

AU - Kubo, Michiko

AU - Kinoshita, Mitsuhiro

AU - Takechi, Katsuya

AU - Uyama, Naoto

AU - Yamanaka, Moriaki

AU - Terazawa, Kaori

AU - Toba, Hiroaki

AU - Bando, Yoshimi

AU - Otsuka, Hideki

AU - Harada, Masafumi

PY - 2019/6/1

Y1 - 2019/6/1

N2 - OBJECTIVE: We assessed the diagnostic capacity of dynamic fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) and dual-time-point (DTP) PET/CT to explore the optimal scan timing for nodal staging in lung cancer. METHODS: Thirty-four patients with lung cancer underwent dynamic and consecutive DTP PET/CT scans. Two readers visually evaluated FDG uptake within each lymph node (LN) and pulmonary artery (metastatic LN: n = 10; nonmetastatic LN: n = 121). For each dynamic and DTP scan, we compared the maximum standardized uptake value (SUVmax) and the retention index of the SUVmax (RI-SUVmax) between metastatic and nonmetastatic LNs. We compared the diagnostic capacity of the dynamic and DTP scans using receiver operating characteristic (ROC) analyses. RESULTS: In the visual analyses of LN metastases, a sensitivity of 20.0-60.0% and specificity of 97.5-100.0% were identified for the first to third dynamic scans. The sensitivity of the 1-h early and 2-h delayed scans was 80.0% and 90.0%, respectively, whereas the specificity was 66.9% and 47.9%, respectively. The visual analysis of the dynamic second phase had the highest accuracy. Semiquantitative analyses revealed that the SUVmax was significantly higher for metastatic LNs than for nonmetastatic LNs in the dynamic second and third phases and the 1-h early and 2-h delayed phases (p < 0.05 for all). The RI-SUVmax was higher in metastatic LNs than in nonmetastatic LNs for the dynamic scan (p = 0.004) and the DTP scan (p = 0.002). The ROC analyses showed that SUV2 and SUV3 had higher performances with high specificity, high negative predictive value, and high accuracy than the other parameters. The area under the ROC curve of the RI-SUV-dual-time-point had the highest value (0.794) without any significant differences between the area under the ROC curves for all parameters (p > 0.05 for all). CONCLUSIONS: Based on the visual and semiquantitative analyses, 18F-FDG dynamic PET/CT exhibited excellent performance with extremely high specificity in the dynamic second phase.

AB - OBJECTIVE: We assessed the diagnostic capacity of dynamic fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) and dual-time-point (DTP) PET/CT to explore the optimal scan timing for nodal staging in lung cancer. METHODS: Thirty-four patients with lung cancer underwent dynamic and consecutive DTP PET/CT scans. Two readers visually evaluated FDG uptake within each lymph node (LN) and pulmonary artery (metastatic LN: n = 10; nonmetastatic LN: n = 121). For each dynamic and DTP scan, we compared the maximum standardized uptake value (SUVmax) and the retention index of the SUVmax (RI-SUVmax) between metastatic and nonmetastatic LNs. We compared the diagnostic capacity of the dynamic and DTP scans using receiver operating characteristic (ROC) analyses. RESULTS: In the visual analyses of LN metastases, a sensitivity of 20.0-60.0% and specificity of 97.5-100.0% were identified for the first to third dynamic scans. The sensitivity of the 1-h early and 2-h delayed scans was 80.0% and 90.0%, respectively, whereas the specificity was 66.9% and 47.9%, respectively. The visual analysis of the dynamic second phase had the highest accuracy. Semiquantitative analyses revealed that the SUVmax was significantly higher for metastatic LNs than for nonmetastatic LNs in the dynamic second and third phases and the 1-h early and 2-h delayed phases (p < 0.05 for all). The RI-SUVmax was higher in metastatic LNs than in nonmetastatic LNs for the dynamic scan (p = 0.004) and the DTP scan (p = 0.002). The ROC analyses showed that SUV2 and SUV3 had higher performances with high specificity, high negative predictive value, and high accuracy than the other parameters. The area under the ROC curve of the RI-SUV-dual-time-point had the highest value (0.794) without any significant differences between the area under the ROC curves for all parameters (p > 0.05 for all). CONCLUSIONS: Based on the visual and semiquantitative analyses, 18F-FDG dynamic PET/CT exhibited excellent performance with extremely high specificity in the dynamic second phase.

KW - Dynamic positron emission tomography (PET)

KW - F-18 fluorodeoxyglucose (FDG)

KW - Lung cancer

KW - Lymph node

KW - Lymphatic metastasis

UR - http://www.scopus.com/inward/record.url?scp=85066963603&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066963603&partnerID=8YFLogxK

U2 - 10.1007/s12149-019-01350-z

DO - 10.1007/s12149-019-01350-z

M3 - Article

C2 - 30911883

AN - SCOPUS:85066963603

VL - 33

SP - 414

EP - 423

JO - Annals of Nuclear Medicine

JF - Annals of Nuclear Medicine

SN - 0914-7187

IS - 6

ER -